Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

32.62
Delayed Data
As of 3:59pm ET
 -0.24 / -0.73%
Today’s Change
16.64
Today|||52-Week Range
43.89
-8.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.9B

Company Description

ACADIA Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical products. It caters to patients with central nervous system disorders such as Parkinson's disease, Alzheimer's disease, Schizophrenia, chronic pain, and Glaucoma. Its portfolio consists of Nuplazid, Pimavanserin, Adrenergic, and Muscarinic. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Contact Information

ACADIA Pharmaceuticals, Inc.
3611 Valley Centre Drive
San Diego California 92130-3331
P:(858) 558-2871
Investor Relations:

Employees

Shareholders

Mutual fund holders53.36%
Other institutional46.75%
Individual stakeholders31.58%

Top Executives

Stephen R. DavisPresident, Chief Executive Officer & Director
James A. NashVice President-Technology Development & Operations
Todd S. YoungEVP, Chief Financial & Accounting Officer
James OwenChief Medical Officer & SVP-Clinical Development
Ryan E. BrownChief Compliance Officer